vs
Side-by-side financial comparison of MODIV INDUSTRIAL, INC. (MDV) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
MODIV INDUSTRIAL, INC. is the larger business by last-quarter revenue ($11.1M vs $9.1M, roughly 1.2× Protalix BioTherapeutics, Inc.). MODIV INDUSTRIAL, INC. runs the higher net margin — 11.0% vs -60.3%, a 71.3% gap on every dollar of revenue. On growth, MODIV INDUSTRIAL, INC. posted the faster year-over-year revenue change (-5.6% vs -49.9%). Over the past eight quarters, MODIV INDUSTRIAL, INC.'s revenue compounded faster (-3.8% CAGR vs -6.7%).
MODIV INDUSTRIAL, INC. is a U.S.-based industrial real estate enterprise focused on acquiring, owning and operating high-quality industrial properties mainly located in key logistics and distribution hubs across North America. It serves tenants from sectors including e-commerce fulfillment, manufacturing and third-party logistics, addressing rising demand for modern supply chain infrastructure.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
MDV vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.1M | $9.1M |
| Net Profit | $1.2M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 45.8% | -51.1% |
| Net Margin | 11.0% | -60.3% |
| Revenue YoY | -5.6% | -49.9% |
| Net Profit YoY | -22.0% | -184.8% |
| EPS (diluted) | $0.02 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.1M | $9.1M | ||
| Q3 25 | $11.7M | $17.9M | ||
| Q2 25 | $11.8M | $15.7M | ||
| Q1 25 | $11.8M | $10.1M | ||
| Q4 24 | $11.7M | $18.2M | ||
| Q3 24 | $11.7M | $18.0M | ||
| Q2 24 | $11.4M | $13.5M | ||
| Q1 24 | $12.0M | — |
| Q4 25 | $1.2M | $-5.5M | ||
| Q3 25 | $1.0M | $2.4M | ||
| Q2 25 | $-2.0M | $164.0K | ||
| Q1 25 | $829.0K | $-3.6M | ||
| Q4 24 | $1.6M | $6.5M | ||
| Q3 24 | $-587.0K | $3.2M | ||
| Q2 24 | $1.3M | $-2.2M | ||
| Q1 24 | $3.7M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 45.8% | -51.1% | ||
| Q3 25 | 41.4% | 11.9% | ||
| Q2 25 | 9.8% | 7.5% | ||
| Q1 25 | 40.2% | -41.0% | ||
| Q4 24 | 45.4% | 39.6% | ||
| Q3 24 | 42.0% | 22.2% | ||
| Q2 24 | 44.6% | -18.0% | ||
| Q1 24 | 55.6% | — |
| Q4 25 | 11.0% | -60.3% | ||
| Q3 25 | 9.0% | 13.2% | ||
| Q2 25 | -17.1% | 1.0% | ||
| Q1 25 | 7.0% | -35.8% | ||
| Q4 24 | 13.3% | 35.6% | ||
| Q3 24 | -5.0% | 18.0% | ||
| Q2 24 | 11.6% | -16.4% | ||
| Q1 24 | 31.1% | — |
| Q4 25 | $0.02 | $-0.06 | ||
| Q3 25 | $0.00 | $0.03 | ||
| Q2 25 | $-0.32 | $0.00 | ||
| Q1 25 | $-0.01 | $-0.05 | ||
| Q4 24 | $0.07 | $0.10 | ||
| Q3 24 | $-0.18 | $0.03 | ||
| Q2 24 | $0.03 | $-0.03 | ||
| Q1 24 | $0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.4M | $14.7M |
| Total DebtLower is stronger | $261.5M | — |
| Stockholders' EquityBook value | $162.7M | $48.2M |
| Total Assets | $476.5M | $82.3M |
| Debt / EquityLower = less leverage | 1.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.4M | $14.7M | ||
| Q3 25 | $8.3M | $13.6M | ||
| Q2 25 | $5.8M | $17.9M | ||
| Q1 25 | $6.2M | $19.5M | ||
| Q4 24 | $11.5M | $19.8M | ||
| Q3 24 | $6.8M | $27.4M | ||
| Q2 24 | $18.9M | $23.4M | ||
| Q1 24 | $18.4M | — |
| Q4 25 | $261.5M | — | ||
| Q3 25 | $279.7M | — | ||
| Q2 25 | $279.7M | — | ||
| Q1 25 | $279.7M | — | ||
| Q4 24 | $279.8M | — | ||
| Q3 24 | $279.7M | — | ||
| Q2 24 | $279.7M | — | ||
| Q1 24 | $279.6M | — |
| Q4 25 | $162.7M | $48.2M | ||
| Q3 25 | $164.8M | $52.9M | ||
| Q2 25 | $165.6M | $49.9M | ||
| Q1 25 | $171.1M | $45.2M | ||
| Q4 24 | $190.1M | $43.2M | ||
| Q3 24 | $186.3M | $32.4M | ||
| Q2 24 | $187.0M | $28.6M | ||
| Q1 24 | $188.0M | — |
| Q4 25 | $476.5M | $82.3M | ||
| Q3 25 | $499.6M | $82.3M | ||
| Q2 25 | $498.9M | $78.5M | ||
| Q1 25 | $506.8M | $73.9M | ||
| Q4 24 | $507.8M | $73.4M | ||
| Q3 24 | $507.4M | $61.6M | ||
| Q2 24 | $519.5M | $91.5M | ||
| Q1 24 | $522.5M | — |
| Q4 25 | 1.61× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.69× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.50× | — | ||
| Q2 24 | 1.50× | — | ||
| Q1 24 | 1.49× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.0M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | 12.34× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.0M | $2.0M | ||
| Q3 25 | $4.1M | $-3.7M | ||
| Q2 25 | $3.9M | $-5.2M | ||
| Q1 25 | $3.0M | $-5.1M | ||
| Q4 24 | $18.2M | $4.0M | ||
| Q3 24 | $5.1M | $4.1M | ||
| Q2 24 | $4.7M | $-3.6M | ||
| Q1 24 | $3.0M | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | 12.34× | — | ||
| Q3 25 | 3.95× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | 3.68× | — | ||
| Q4 24 | 11.72× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | 3.55× | — | ||
| Q1 24 | 0.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MDV
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
